Stock Scorecard
Stock Summary for Arbutus Biopharma Corp (ABUS) - $4.88 as of 9/25/2026 7:00:49 PM EST
Total Score
15 out of 30
Safety Score
39 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for ABUS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ABUS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ABUS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ABUS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ABUS (39 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 9 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ABUS
Financial Details for ABUS
Company Overview |
|
|---|---|
| Ticker | ABUS |
| Company Name | Arbutus Biopharma Corp |
| Country | USA |
| Description | Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2026 |
| Next Earnings Date | 11/12/2026 |
Stock Price History |
|
| Last Day Price | 4.88 |
| Price 4 Years Ago | 2.33 |
| Last Day Price Updated | 9/25/2026 7:00:49 PM EST |
| Last Day Volume | 6,262,978 |
| Average Daily Volume | 4,981,451 |
| 52-Week High | 5.45 |
| 52-Week Low | 3.50 |
| Last Price to 52 Week Low | 39.43% |
Valuation Measures |
|
| Trailing PE | 6.18 |
| Industry PE | 27.67 |
| Sector PE | 65.40 |
| 5-Year Average PE | -6.08 |
| Free Cash Flow Ratio | 48.80 |
| Industry Free Cash Flow Ratio | 34.82 |
| Sector Free Cash Flow Ratio | 36.01 |
| Current Ratio Most Recent Quarter | 81.42 |
| Total Cash Per Share | 0.10 |
| Book Value Per Share Most Recent Quarter | 1.31 |
| Price to Book Ratio | 3.83 |
| Industry Price to Book Ratio | 12.01 |
| Sector Price to Book Ratio | 11.82 |
| Price to Sales Ratio Twelve Trailing Months | 5.32 |
| Industry Price to Sales Ratio Twelve Trailing Months | 58.05 |
| Sector Price to Sales Ratio Twelve Trailing Months | 42.89 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 198,106,000 |
| Market Capitalization | 966,757,280 |
| Institutional Ownership | 72.77% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 52.09% |
| Reported EPS 12 Trailing Months | 0.79 |
| Reported EPS Past Year | 1.16 |
| Reported EPS Prior Year | -0.24 |
| Net Income Twelve Trailing Months | 153,054,000 |
| Net Income Past Year | -33,501,000 |
| Net Income Prior Year | -69,920,000 |
| Quarterly Revenue Growth YOY | -90.60% |
| 5-Year Revenue Growth | 15.29% |
| Operating Margin Twelve Trailing Months | -567.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 19,171,000 |
| Total Cash Past Year | 18,008,000 |
| Total Cash Prior Year | 36,330,000 |
| Net Cash Position Most Recent Quarter | 19,171,000 |
| Net Cash Position Past Year | 18,008,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 76,576,000 |
| Total Stockholder Equity Prior Year | 97,366,000 |
| Total Stockholder Equity Most Recent Quarter | 258,733,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -38,687,318 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.20 |
| Free Cash Flow Past Year | -39,637,000 |
| Free Cash Flow Prior Year | -65,032,000 |
Options |
|
| Put/Call Ratio | 1.01 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.05 |
| MACD Signal | 0.08 |
| 20-Day Bollinger Lower Band | 4.05 |
| 20-Day Bollinger Middle Band | 4.67 |
| 20-Day Bollinger Upper Band | 5.30 |
| Beta | 0.62 |
| RSI | 50.68 |
| 50-Day SMA | 4.48 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 9/25/2026 4:20:39 PM EST |